Photo from Patrick Forde/Twitter
Oct 18, 2023, 16:51
Patrick Forde: ALINA adjuvant alectinib vs chemo for ALK post resected lung cancer
Quoting Patrick Forde, Co-Director of the Division of Upper Aerodigestive Malignancies Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, on X/Twitter:
ALINA adjuvant alectinib vs chemo for ALK post resected lung cancer. Again unfortunate re-data leak but a sneak peek looks good. HR 0.24 favoring alectinib 30% improvement in DFS at 3 years. Adjuvant chemo followed by alectinib is likely the path forward.
Source: Patrick Forde/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19